Comparative Pharmacology
Head-to-head clinical analysis: NORMINEST FE versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORMINEST FE versus TRI SPRINTEC.
NORMINEST FE vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive